Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Cranial Radiotherapy in Acute Lymphoblastic Leukemia

Assessing its impact on relapse risk

Cranial radiotherapy (CRT) does not have an impact on the risk of relapse in children with acute lymphoblastic leukemia (ALL) treated on contemporary protocols, according to a study of 16,623 patients aged 1 to 18 years with newly diagnosed ALL. Researchers found:

  • Although there was significant heterogeneity in all outcome end points according to trial, CRT was associated with a reduced risk of relapse only in the small subgroup of patients with overt CNS disease at diagnosis, who had significantly lower risk of isolated CNS relapse (4% with CRT, 17% without), and a trend toward lower risk of any CNS relapse (7% with CRT, 17% without).
  • But, that group had a relatively high rate of events regardless of whether they did (32%) or did not (39%) receive CRT.

Citation: Vora A, Andreano A, Pui CH, et al. Influence of cranial radiotherapy on outcome in children with acute lymphoblastic leukemia treated with contemporary therapy. [Published online ahead of print January 11, 2016]. J Clin Oncol. doi:10.1200/JCO.2015.64.2850.